Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review

References

• Laurieri N, Sim E, editors. Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics. Singapore: World Scientific Publishing; 2018. ISBN: 978-981-3232-00-6.
   Google Scholar
• Husain A, Zhang X, Doll MA, et al. Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues. Drug Metab Dispos. 2007 May;35(5):721–727.
   PubMed Web of Science ®Google Scholar
• Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev. 1985 Mar;37(1):25–79.
   PubMed Web of Science ®Google Scholar
• McDonagh EM, Boukouvala S, Aklillu E, et al. PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics. 2014 Aug;24(8):409–425.
   PubMed Web of Science ®Google Scholar
• Agundez JA, Garcia-Martin E. Human arylamine N-acetyltransferases type 2: phenotype correlation with genotype-A clinical perspective. In: Laurieri N, Sim E, editors. Chapter 1.3, Arylamine N-acetyltransferases in health and disease: from pharmacogenetics to drug discovery and diagnostics. Singapore: World Scientific Publishing; 2018. ISBN: 978-981-3232-00-6.
   Google Scholar
• Mitchell SC. N-acetyltransferase: the practical consequences of polymorphic activity in man. Xenobiotica. 2020 Jan;50(1):77–91.
   PubMedGoogle Scholar
• Husain A, Zhang X, Doll MA, et al. Functional analysis of the human N-acetyltransferase 1 major promoter: quantitation of tissue expression and identification of critical sequence elements. Drug Metab Dispos. 2007 Sept;35(9):1649–1656.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Drakoulis N, Brockmöller J, et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995 Sept;57(3):581–592.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Brockmöller J, Mrozikiewicz PM, et al. Arylamine N-acetyltransferase activity in man. Drug Metab Rev. 1999 May;31(2):489–502.
   PubMed Web of Science ®Google Scholar
• Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960 Aug 13;2(5197):485–491.
   PubMed Web of Science ®Google Scholar
• Gelber R, Peters JH, Gordon GR, et al. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar–Apr;12(2):225–238.
   PubMed Web of Science ®Google Scholar
• Campbell W, Tilstone WJ, Lawson DH, et al. Acetylator phenotype and the clinical pharmacology of slow-release procainamide. Br J Clin Pharmacol. 1976 Dec;3(6):1023–1026.
   PubMed Web of Science ®Google Scholar
• Evans DA, White TA. Human acetylation polymorphism. J Lab Clin Med. 1964 Mar;63:394–403.
   PubMed Web of Science ®Google Scholar
• Evans DA. An improved and simplified method of detecting the acetylator phenotype. J Med Genet. 1969 Dec;6(4):405–407.
   PubMedGoogle Scholar
• Timbrell JA, Harland SJ, Facchini V. Polymorphic acetylation of hydralazine. Clin Pharmacol Ther. 1980 Sept;28(3):350–355.
   PubMed Web of Science ®Google Scholar
• Facchini V, Timbrell JA. Further evidence for an acetylator phenotype difference in the metabolism of hydralazine in man. Br J Clin Pharmacol. 1981 Apr;11(4):345–351.
   PubMed Web of Science ®Google Scholar
• Clark DW. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Drugs. 1985 Apr;29(4):342–375.
   PubMed Web of Science ®Google Scholar
• Relling MV. Polymorphic drug metabolism. Clin Pharm. 1989 Dec;8(12):852–863.
   PubMedGoogle Scholar
• Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):29–42.
   PubMed Web of Science ®Google Scholar
• Hein DW. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol. 2009 Apr;5(4):353–366.
   PubMed Web of Science ®Google Scholar
• Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2012 Jan;13(1):31–41.
   PubMed Web of Science ®Google Scholar
• Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006 Mar 13;25(11):1649–1658.
   PubMed Web of Science ®Google Scholar
• Walker K, Ginsberg G, Hattis D, et al. Genetic polymorphism in N-acetyltransferase (NAT): population distribution of NAT1 and NAT2 activity. J Toxicol Env Heal B. 2009;12(5–6):440–472.
   Google Scholar
• Hein DW, Doll MA. Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype. Arch Toxicol. 2017 Aug;91(8):2827–2835.
   PubMed Web of Science ®Google Scholar
• Deitz AC, Rothman N, Rebbeck TR, et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev. 2004 Sept;13(9):1543–1546.
   PubMed Web of Science ®Google Scholar
• Selinski S, Blaszkewicz M, Lehmann ML, et al. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics. 2011 Oct;21(10):673–678.
   PubMed Web of Science ®Google Scholar
• Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979;4:401–422.
   PubMed Web of Science ®Google Scholar
• Doll MA, Salazar-González RA, Bodduluri S, et al. Arylamine N-acetyltransferase 2 genotype-dependent N-acetylation of isoniazid in cryopreserved human hepatocytes. Acta Pharm Sin B. 2017 Jul 7;4:517–522.
   Google Scholar
• Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Memorias Do Instituto Oswaldo Cruz. 2011 Sept;106(6):716–724.
   PubMed Web of Science ®Google Scholar
• Richardson M, Kirkham J, Dwan K, et al. NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019 Mar 1;23(3):293–305.
   PubMed Web of Science ®Google Scholar
• Khan S, Mandal RK, Elasbali AM, et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence. Biosci Rep. 2019 Jan 31;39:1.
   Web of Science ®Google Scholar
• Parkin DP, Vandenplas S, Botha FJ, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med. 1997 May;155(5):1717–1722.
   PubMed Web of Science ®Google Scholar
• Huerta-García A, Medellín-Garibay S, Ortiz-Álvarez A, et al. Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. Int J Clin Pharm. 2020. DOI:10.1007/s11096-020-01086-1.
   PubMed Web of Science ®Google Scholar
• Smith CA, Wadelius M, Gough AC, et al. A simplified assay for the arylamine N-acetyltransferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet. 1997 Sept;34(9):758–760.
   PubMed Web of Science ®Google Scholar
• Donald PR, Parkin DP, Seifart HI, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol. 2007 July;63(7):633–639.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Srivastava S, Gumbo T. Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis. 2012 July;55(2):169–177.
   PubMed Web of Science ®Google Scholar
• Azuma J, Ohno M, Kubota R, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013 May;69(5):1091–1101.
   PubMed Web of Science ®Google Scholar
• Jung JA, Kim TE, Lee H, et al. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther. 2015;9:5433–5438.
   PubMed Web of Science ®Google Scholar
• Suvichapanich S, Fukunaga K, Zahroh H, et al. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenet Genomics. 2018 July;28(7):167–176.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ohno M, Azuma J. Future of pharmacogenetics-based therapy for tuberculosis. Pharmacogenomics. 2014 Apr;15(5):601–607.
   PubMed Web of Science ®Google Scholar
• Choi R, Jeong BH, Koh WJ, et al. Recommendations for optimizing tuberculosis treatment: therapeutic drug monitoring, pharmacogenetics, and nutritional status considerations. Ann Lab Med. 2017 Mar;37(2):97–107.
   PubMed Web of Science ®Google Scholar
• Motta I, Calcagno A, Bonora S. Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):59–82.
   PubMed Web of Science ®Google Scholar
• Jing W, Zong Z, Tang B, et al. Population pharmacokinetic analysis of isoniazid among pulmonary tuberculosis patients from China. Antimicrob Agents Chemother. 2020 Feb 21;64:3.
   Web of Science ®Google Scholar
• Cohn JN, McInnes GT, Shepherd AM. Direct-acting vasodilators. J Clin Hypertens (Greenwich, CT). 2011 Sept;13(9):690–692.
   PubMed Web of Science ®Google Scholar
• Han LW, Ryu RJ, Cusumano M, et al. Effect of N-acetyltransferase 2 genotype on the pharmacokinetics of hydralazine during pregnancy. J Clin Pharmacol. 2019 Dec;59(12):1678–1689.
   PubMed Web of Science ®Google Scholar
• Collins KS, Raviele ALJ, Elchynski AL, et al. Genotype-guided hydralazine therapy. Am J Nephrol. 2020;14:1–13.
   Google Scholar
• Timbrell JA, Harland SJ, Facchini V. Effect of dose on acetylator phenotype distribution of hydralazine. Clin Pharmacol Ther. 1981 Mar;29(3):337–343.
   PubMed Web of Science ®Google Scholar
• Shepherd AM, McNay JL, Ludden TM, et al. Plasma concentration and acetylator phenotype determine response to oral hydralazine. Hypertens. 1981 Sept-Oct;3(5):580–585.
   PubMed Web of Science ®Google Scholar
• Spinasse LB, Santos AR, Suffys PN, et al. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. Pharmacogenomics. 2014 Feb;15(2):169–178.
   PubMed Web of Science ®Google Scholar
• Dueñas-Gonzalez A, Coronel J, Cetina L, et al. Hydralazine-valproate: a repositioned drug combination for the epigenetic therapy of cancer. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1433–1444.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Fierro A, Vasquez-Bahena D, Taja-Chayeb L, et al. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype. Int J Clin Pharmacol Ther. 2011 Aug;49(8):519–524.
   PubMed Web of Science ®Google Scholar
• Arce C, Pérez-Plasencia C, González-Fierro A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006 Dec 20;1(1):e98.
   PubMed Web of Science ®Google Scholar
• Garcés-Eisele SJ, Cedillo-Carvallo B, Reyes-Núñez V, et al. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure. J Clin Pharm Ther. 2014 Aug;39(4):368–375.
   PubMed Web of Science ®Google Scholar
• Allen CE, Doll MA, Hein DW. N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276–1281.
   PubMed Web of Science ®Google Scholar
• Taja-Chayeb L, González-Fierro A, Miguez-Muñoz C, et al. Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype-genotype correlation with the sulfamethazine test. Pharmacogenet Genomics. 2011 Dec;21(12):894–901.
   PubMed Web of Science ®Google Scholar
• Chen B, Zhang WX, Cai WM. The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur J Clin Pharmacol. 2006 May;62(5):355–359.
   PubMed Web of Science ®Google Scholar
• Doll MA, Zang Y, Moeller T, et al. Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes. J Pharmacol Exp Ther. 2010 Aug;334(2):540–544.
   PubMed Web of Science ®Google Scholar
• Habil MR, Doll MA, Hein DW. N-acetyltransferase 2 acetylator genotype-dependent N-acetylation of 4-aminobiphenyl in cryopreserved human hepatocytes. Pharmacogenet Genomics. 2020 Apr;30(3):61–65.
   PubMed Web of Science ®Google Scholar
• Doll MA, Hein DW. Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes. Arch Toxicol. 2017 July;91(7):2655–2661.
   PubMed Web of Science ®Google Scholar
• Mantegazza R. Amifampridine tablets for the treatment of lambert-eaton myasthenic syndrome. Expert Rev Clin Pharmacol. 2019 Nov;12(11):1013–1018.
   PubMed Web of Science ®Google Scholar
• Haroldsen PE, Garovoy MR, Musson DG, et al. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
   PubMed Web of Science ®Google Scholar
• Woosley RL, Drayer DE, Reidenberg MM, et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med. 1978 May 25;298(21):1157–1159.
   PubMed Web of Science ®Google Scholar
• Okumura K, Kita T, Chikazawa S, et al. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. Clin Pharmacol Ther. 1997 May;61(5):509–517.
   PubMed Web of Science ®Google Scholar
• Schröder H, Evans DA. The polymorphic acetylation of sulphapyridine in man. J Med Genet. 1972 June;9(2):168–171.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Komada F, Kita T, et al. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res. 2004 Feb;21(2):324–329.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Ieiri I, Kusuhara H, et al. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans. Clin Pharmacol Ther. 2008 July;84(1):95–103.
   PubMed Web of Science ®Google Scholar
• Ma JJ, Liu CG, Li JH, et al. Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Clin Chim Acta. 2009 Sept;407(1–2):30–35.
   PubMed Web of Science ®Google Scholar
• Yee J, Kim SM, Han JM, et al. The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis. Sci Rep. 2020 Feb 27;10(1):3658.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Mick R, Berezin F, et al. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):573–579.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Mick R, Berezin F, et al. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15;53(10 Suppl):2304–2308.
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Mick R, Janisch L, et al. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb;6(1):93–101.
   PubMedGoogle Scholar
• Innocenti F, Iyer L, Ratain MJ. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001 Apr;29(4 Pt 2):596–600.
   PubMed Web of Science ®Google Scholar
• Lutz M. Metamizole (dipyrone) and the liver: a review of the literature. J Clin Pharmacol. 2019 Nov;59(11):1433–1442.
   PubMed Web of Science ®Google Scholar
• Bonkowsky JL, Frazer JK, Buchi KF, et al. Metamizole use by Latino immigrants: a common and potentially harmful home remedy. Pediatrics. 2002 June;109(6):e98.
   PubMed Web of Science ®Google Scholar
• Garcia S, Canoniero M, Lopes G, et al. Metamizole use among Hispanics in Miami: report of a survey conducted in a primary care setting. South Med J. 2006 Sept;99(9):924–926.
   PubMed Web of Science ®Google Scholar
• Martínez C, Andreu I, Amo G, et al. Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochem Pharmacol. 2014 Dec 1;92(3):457–466.
   PubMed Web of Science ®Google Scholar
• García-Martín E, Esguevillas G, Blanca-López N, et al. Genetic determinants of metamizole metabolism modify the risk of developing anaphylaxis. Pharmacogenet Genomics. 2015 Sept;25(9):462–464.
   PubMed Web of Science ®Google Scholar
• Zanrosso CW, Emerenciano M, Gonçalves BA, et al. N-acetyltransferase 2 polymorphisms and susceptibility to infant leukemia with maternal exposure to dipyrone during pregnancy. Cancer Epidemiol Biomarkers Prev. 2010 Dec;19(12):3037–3043.
   PubMed Web of Science ®Google Scholar
• Olivera M, Martínez C, Gervasini G, et al. Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan 1;1:3–5.
   PubMedGoogle Scholar
• Conway LP, Rendo V, Correia MSP, et al. Unexpected acetylation of endogenous aliphatic amines by arylamine N-acetyltransferase NAT2. Angew Chem. 2020;59(34):14342–14346.
   Google Scholar
• Ruiz JD, Martínez C, Anderson K, et al. The differential effect of NAT2 variant alleles permits refinement in phenotype inference and identifies a very slow acetylation genotype. PLoS One. 2012;7(9):e44629.
   PubMed Web of Science ®Google Scholar
• Selinski S, Blaszkewicz M, Ickstadt K, et al. Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk. Arch Toxicol. 2013 Dec;87(12):2129–2139.
   PubMed Web of Science ®Google Scholar
• Zang Y, Doll MA, Zhao S, et al. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis. 2007 Aug;28(8):1665–1671.
   PubMed Web of Science ®Google Scholar
• World Health Organization Global Tuberculosis Executive Summary. 2019 [cited 2020 May 12]. https://www.who.int/tb/publications/global_report/tb19_Exec_Sum_12Nov2019.pdf?ua=1
   Google Scholar
• Glaziou P. Predicted impact of the COVID-19 pandemic on global tuberculosis deaths in 2020. medRxiv. 2020. 2020.04.28.20079582. DOI:10.1101/2020.04.28.20079582
   Google Scholar
• Saunders MJ, Evans CA. COVID-19, tuberculosis and poverty: preventing a perfect storm. Eur Respir J. 2020 July;56(1). PubMed PMID: 32444399; PubMed Central PMCID: PMCPMC7243392. DOI:10.1183/13993003.01348-2020
   Web of Science ®Google Scholar
• Villarino ME, Scott NA, Weis SE, et al. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015 Mar;169(3):247–255. PubMed PMID: 25580725; PubMed Central PMCID: PMCPMC6624831.
   PubMed Web of Science ®Google Scholar
• Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother. 2005 May;49(5):1733–1738.
   PubMed Web of Science ®Google Scholar
• Rens NE, Uyl-de Groot CA, Goldhaber-Fiebert JD, et al. Cost-effectiveness of a pharmacogenomic test for stratified isoniazid dosing in treatment of active tuberculosis. Clin Infect Dis. 2020 Jan 6:ciz1212. DOI:10.1093/cid/ciz1212. Epub ahead of print. PMID: 31905381.
   PubMed Web of Science ®Google Scholar
• Relling MV, Klein TE. CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011 Mar;89(3):464–467.
   PubMed Web of Science ®Google Scholar
• Haga SB. Challenges of development and implementation of point of care pharmacogenetic testing. Expert Rev Mol Diagn. 2016 Sept;16(9):949–960. PubMed PMID: 27402403; PubMed Central PMCID: PMCPMC6709578.
   PubMed Web of Science ®Google Scholar